◈ X-Research
← Category Events
What happened

On April 14, 2026, Bloomberg reported Anthropic is fielding new investor offers at an $800B+ valuation — nearly tripling its $30B Series G valuation from February 2026. On the same day, Vas Narasimhan, former Novartis CEO, was appointed to the Anthropic board. Anthropic's annualized revenue run-rate has crossed $30B, and the company is now evaluating custom silicon development (analogous to Google's TPU and Meta's MTIA programs). The $800B valuation approaches OpenAI's territory, reflecting intense competitive pressure and Anthropic's rapid share gains (now at 30.6% enterprise share, up from 24.4% — closing on OpenAI's 35.2%). The Narasimhan appointment signals explicit enterprise healthcare expansion — Novartis operates in 140 countries with $48B in revenue; his network directly opens regulated-industry enterprise doors.

Why it matters for Seva's category

For enterprise buyers and operators: the $800B valuation context means Anthropic has effectively unlimited runway — vendor viability concerns are off the table for Claude-based tools. The Narasimhan signal is more significant: it accelerates Claude adoption in healthcare and pharmaceutical enterprise, expanding the buyer universe for AI GTM tools targeting those verticals. The custom silicon evaluation is an infrastructure moat story — Anthropic moving toward owning compute changes its cost structure and long-term pricing. For AI GTM operators: the competitive dynamic (Anthropic closing on OpenAI in enterprise share) is relevant to stack decisions — the gap is narrowing and trajectory favors Claude in regulated verticals.

Content angles
https://www.bloomberg.com/news/articles/2026-04-1… ↗